8-KLeadership ChangesExhibits & Filings

LAM RESEARCH CORP 8-K Report, Executive Changes (Feb 9, 2023)

Filed February 9, 2023For Securities:LRCX

Summary

Lam Research Corporation (LRCX) announced a significant addition to its Board of Directors with the appointment of Ho Kyu Kang, effective February 7, 2023. Dr. Kang brings extensive experience in the semiconductor industry, having held senior leadership roles at Samsung Electronics for over two decades, specializing in research and development, process development, and technology innovation. His academic background, including a Ph.D. from Stanford University, and prior board experience with semiconductor research consortia, will undoubtedly enhance the company's strategic direction and technological insight. In addition to the board appointment, the company's Compensation and Human Resources Committee amended and restated the 2004 Executive Incentive Plan. These amendments primarily involve clarifying that awards are subject to the company's clawback policy and removing provisions related to a now-repealed IRS tax code exception, reflecting administrative and regulatory updates. Investors should note that Dr. Kang's appointment is routine and he will receive standard director compensation and an indemnification agreement.

Key Highlights

  • 1Lam Research appointed Ho Kyu Kang to its Board of Directors, effective February 7, 2023, increasing the board size to ten members.
  • 2Dr. Kang possesses extensive semiconductor industry expertise, previously serving as Executive Vice President and Head of Research at Samsung Electronics' R&D Center.
  • 3His background includes significant experience in process development and advanced technology development at Samsung.
  • 4Dr. Kang holds a Ph.D. in Material Science and Engineering from Stanford University.
  • 5The company amended and restated its 2004 Executive Incentive Plan, clarifying clawback policy application and updating for tax code changes.
  • 6Dr. Kang's appointment is not based on any undisclosed arrangements and he has no disqualifying relationships with existing officers or directors.
  • 7Dr. Kang will receive compensation consistent with the company's non-employee director policies and a standard indemnification agreement.

Frequently Asked Questions